Concert Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia…
Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543,…
Read More...
Read More...